Intravenous iron supplementation for the treatment of chemotherapy-induced anaemia – systematic review and meta-analysis of randomised controlled trials

References

• Ludwig H, Van Belle S, Barrett-Lee P, Birgegard G, Bokemeyer C, Gascon P, . The European Cancer Anaemia Survey (ECAS): A large, multinational, prospective survey defining the prevalence, incidence, and treatment of anaemia in cancer patients. Eur J Cancer 2004;40:2293–306.
   PubMed Web of Science ®Google Scholar
• Weiss G, Goodnough LT. Anemia of chronic disease. N Engl J Med 2005;352:1011–23.
   PubMed Web of Science ®Google Scholar
• Bohlius J, Weingart O, Trelle S, Engert A. Cancer-related anemia and recombinant human erythropoietin – an updated overview. Nat Clin Pract Oncol 2006;3:152–64.
   PubMedGoogle Scholar
• Wauters I, Vansteenkiste J. Erythropoiesis-stimulating agents in cancer patients: Reflections on safety. Expert Rev Clin Pharmacol 2011;4:467–76.
   PubMedGoogle Scholar
• Bohlius J, Langensiepen S, Schwarzer G, Seidenfeld J, Piper M, Bennett C, . Recombinant human erythropoietin and overall survival in cancer patients: Results of a comprehensive meta-analysis. J Natl Cancer Inst 2005;97:489–98.
   PubMed Web of Science ®Google Scholar
• Schrijvers D, De Samblanx H, Roila F. Erythropoiesis- stimulating agents in the treatment of anaemia in cancer patients: ESMO Clinical Practice Guidelines for use. Ann Oncol 2010;21(Suppl 5):v244–7.
   Google Scholar
• Rizzo JD, Brouwers M, Hurley P, Seidenfeld J, Arcasoy MO, Spivak JL, . American Society of Clinical Oncology/American Society of Hematology clinical practice guideline update on the use of epoetin and darbepoetin in adult patients with cancer. J Clin Oncol 2010;28:4996–5010.
   PubMed Web of Science ®Google Scholar
• NCCN. Clinical Practice Guidelines in Oncology: Cancer- and chemotherapy-induced anemia, version 2. 2011. Available at: http://www. nccn.org/professionals/physician_gls/PDF/anemia.pdf 2011 (accessed 2012 February 1)
   Google Scholar
• Bokemeyer C, Aapro MS, Courdi A, Foubert J, Link H, Osterborg A, . EORTC guidelines for the use of erythropoietic proteins in anaemic patients with cancer: 2006 update. Eur J Cancer 2007;43:258–70.
   PubMed Web of Science ®Google Scholar
• Goodnough LT. Erythropoietin and iron-restricted erythropoiesis. Exp Hematol 2007;35:167–72.
   PubMed Web of Science ®Google Scholar
• Hedenus M, Birgegard G, Nasman P, Ahlberg L, Karlsson T, Lauri B, . Addition of intravenous iron to epoetin beta increases hemoglobin response and decreases epoetin dose requirement in anemic patients with lymphoproliferative malignancies: A randomized multicenter study. Leukemia 2007;21:627–32.
   PubMed Web of Science ®Google Scholar
• Hedenus M, Birgegard G. The role of iron supplementation during epoietin treatment for cancer-related anemia. Med Oncol 2009;26:105–15.
   PubMed Web of Science ®Google Scholar
• Henry DH. Parenteral iron therapy in cancer-associated anemia. Hematology Am Soc Hematol Educ Program 2010; 2010:351–6.
   PubMedGoogle Scholar
• Steensma DP, Sloan JA, Dakhil SR, Dalton R, Kahanic SP, Prager DJ, . Phase III, randomized study of the effects of parenteral iron, oral iron, or no iron supplementation on the erythropoietic response to darbepoetin alfa for patients with chemotherapy-associated anemia. J Clin Oncol 2010; 29:97–105.
   PubMed Web of Science ®Google Scholar
• Steensma DP, Sasu BJ, Sloan JA, Tomita D, Loprinzi CL, . The relationship between serum hepcidin levels and clinical outcomes in patients with chemotherapy-associated anemia treated in a controlled trial. J Clin Oncol 2011 ASCO Annual meeting proceedings 2011;29(15 Suppl):9031.
   Google Scholar
• Higgins JPT, Green S, editors. Cochrane handbook for systematic reviews of interventions: version 5.1.0. The Cochrane Collaboration, 2011. Available from http://www.cochrane-handbook.org (accessed 2011 December 1)
   Google Scholar
• DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials 1986;7:177–88.
   PubMed Web of Science ®Google Scholar
• Dangsuwan P, Manchana T. Blood transfusion reduction with intravenous iron in gynecologic cancer patients receiving chemotherapy. Gynecol Oncol 2010;116:522–5.
   PubMed Web of Science ®Google Scholar
• Kim YT, Kim SW, Yoon BS, Cho HJ, Nahm EJ, Kim SH, . Effect of intravenously administered iron sucrose on the prevention of anemia in the cervical cancer patients treated with concurrent chemoradiotherapy. Gynecol Oncol 2007;105:199–204.
   PubMed Web of Science ®Google Scholar
• Beguin Y, Maertens J, De Prijck B, Schots R, Frere P, Bonnet C, . Darbepoetin-alfa and i. v. iron administration after autologous hematopoietic stem cell transplantation: A prospective randomized multicenter trial. Blood (ASH Annual Meeting Abstracts) 2008;112. Abstract 54.
   Google Scholar
• Bellet RE, Ghazal H, Flam M, Drelichman A, Gabrail N, Woytowitz D, . A phase III randomized controlled study comparing iron sucrose intravenously (IV) to no iron treatment of anemia in cancer patients undergoing chemotherapy and erythropoietin stimulating agent (ESA) therapy. J Clin Oncol 2007 ASCO Annual Meeting Proceedings 2007;25: 9109.
   Google Scholar
• Henry DH, Dahl NV, Auerbach M, Tchekmedyian S, Laufman LR. Intravenous ferric gluconate significantly improves response to epoetin alfa versus oral iron or no iron in anemic patients with cancer receiving chemotherapy. Oncologist 2007;12:231–42.
   PubMed Web of Science ®Google Scholar
• Pedrazzoli P, Farris A, Del Prete S, Del Gaizo F, Ferrari D, Bianchessi C, . Randomized trial of intravenous iron supplementation in patients with chemotherapy-related anemia without iron deficiency treated with darbepoetin alpha. J Clin Oncol 2008;26:1619–25.
   PubMed Web of Science ®Google Scholar
• Auerbach M, Ballard H, Trout JR, McIlwain M, Ackerman A, Bahrain H, . Intravenous iron optimizes the response to recombinant human erythropoietin in cancer patients with chemotherapy-related anemia: A multicenter, open-label, randomized trial. J Clin Oncol 2004;22:1301–7.
   PubMed Web of Science ®Google Scholar
• Auerbach M, Silberstein PT, Webb RT, Averyanova S, Ciuleanu TE, Shao J, . Darbepoetin alfa 300 or 500 mcg once every 3 weeks with or without intravenous iron in patients with chemotherapy-induced anemia. Am J Hematol 2010;85:655–63.
   PubMed Web of Science ®Google Scholar
• Bastit L, Vandebroek A, Altintas S, Gaede B, Pinter T, Suto TS, . Randomized, multicenter, controlled trial comparing the efficacy and safety of darbepoetin alpha administered every 3 weeks with or without intravenous iron in patients with chemotherapy-induced anemia. J Clin Oncol 2008;26:1611–8.
   PubMed Web of Science ®Google Scholar
• Clarke H, Pallister CJ. The impact of anaemia on outcome in cancer. Clin Lab Haematol 2005;27:1–13.
   PubMedGoogle Scholar
• Goodnough LT. Risks of blood transfusion. Anesthesiol Clin Nth Am 2005;23:241–52.
   PubMedGoogle Scholar
• Aapro M, Beguin Y, Birgegard G, Gascon P, Hedenus M, Osterborg A. Too-low iron doses and too many dropouts in negative iron trial?J Clin Oncol 2011;29:e525–6; author reply e527–8.
   PubMed Web of Science ®Google Scholar
• Smith RE, Jr.,Aapro MS, Ludwig H, Pinter T, Smakal M, Ciuleanu TE, . Darbepoetin alpha for the treatment of anemia in patients with active cancer not receiving chemotherapy or radiotherapy: Results of a phase III, multicenter, randomized, double-blind, placebo-controlled study. J Clin Oncol 2008;26:1040–50.
   PubMed Web of Science ®Google Scholar
• Wright JR, Ung YC, Julian JA, Pritchard KI, Whelan TJ, Smith C, . Randomized, double-blind, placebo- controlled trial of erythropoietin in non-small-cell lung cancer with disease-related anemia. J Clin Oncol 2007;25: 1027–32.
   PubMed Web of Science ®Google Scholar
• Bohlius J, Schmidlin K, Brillant C, Schwarzer G, Trelle S, Seidenfeld J, . Recombinant human erythropoiesis-stimulating agents and mortality in patients with cancer: A meta-analysis of randomised trials. Lancet 2009;373: 1532–42.
   PubMed Web of Science ®Google Scholar
• Bennett CL, Silver SM, Djulbegovic B, Samaras AT, Blau CA, Gleason KJ, . Venous thromboembolism and mortality associated with recombinant erythropoietin and darbepoetin administration for the treatment of cancer-associated anemia. JAMA 2008;299:914–24.
   PubMed Web of Science ®Google Scholar
• Ludwig H, Crawford J, Osterborg A, Vansteenkiste J, Henry DH, Fleishman A, . Pooled analysis of individual patient-level data from all randomized, double-blind, placebo- controlled trials of darbepoetin alfa in the treatment of patients with chemotherapy-induced anemia. J Clin Oncol 2009;27:2838–47.
   PubMed Web of Science ®Google Scholar
• Petrelli F, Borgonovo K, Cabiddu M, Lonati V, Barni S. Addition of iron to erythropoiesis-stimulating agents in cancer patients: A meta-analysis of randomized trials. J Cancer Res Clin Oncol 2012;138:179–87.
   PubMed Web of Science ®Google Scholar
• Husain A, Myers J, Selby D, Thomson B, Chow E. Subgroups of advanced cancer patients clustered by their symptom profiles: Quality-of-life outcomes. J Palliat Med 2011;14:1246–53.
   PubMed Web of Science ®Google Scholar
• Rozen-Zvi B, Gafter-Gvili A, Paul M, Leibovici L, Shpilberg O, Gafter U. Intravenous versus oral iron supplementation for the treatment of anemia in CKD: Systematic review and meta-analysis. Am J Kidney Dis 2008;52:897–906.
   PubMed Web of Science ®Google Scholar
• Henry DH, Dahl NV, Auerbach MA. Thrombocytosis and venous thromboembolism in cancer patients with chemotherapy induced anemia may be related to ESA induced iron restricted erythropoiesis and reversed by administration of IV iron. Am J Hematol 2012;87:308–10.
   PubMed Web of Science ®Google Scholar
• The Clinical Trials. gov website, a service of the U.S National institutes of Health. Available from: http://clinicaltrials.gov/ct2/show/NCT01101399 (accessed 2012 January 17)
   Google Scholar
• The Clinical Trials.gov website, a service of the U.S National institutes of Health. Available from: http://clinicaltrials.gov/ct2/show/NCT01145638 (accessed 2012 January 17)
   Google Scholar